GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syros Pharmaceuticals Inc (FRA:0S90) » Definitions » EV-to-Revenue

Syros Pharmaceuticals (FRA:0S90) EV-to-Revenue : 11.26 (As of Mar. 04, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Syros Pharmaceuticals EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Syros Pharmaceuticals's enterprise value is €3.99 Mil. Syros Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 was €0.35 Mil. Therefore, Syros Pharmaceuticals's EV-to-Revenue for today is 11.26.

The historical rank and industry rank for Syros Pharmaceuticals's EV-to-Revenue or its related term are showing as below:

FRA:0S90' s EV-to-Revenue Range Over the Past 10 Years
Min: -6.41   Med: 49.99   Max: 1194.31
Current: 10.75

During the past 10 years, the highest EV-to-Revenue of Syros Pharmaceuticals was 1194.31. The lowest was -6.41. And the median was 49.99.

FRA:0S90's EV-to-Revenue is ranked worse than
64.17% of 1030 companies
in the Biotechnology industry
Industry Median: 7.285 vs FRA:0S90: 10.75

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-03-04), Syros Pharmaceuticals's stock price is €0.0575. Syros Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was €0.01. Therefore, Syros Pharmaceuticals's PS Ratio for today is 4.79.


Syros Pharmaceuticals EV-to-Revenue Historical Data

The historical data trend for Syros Pharmaceuticals's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syros Pharmaceuticals EV-to-Revenue Chart

Syros Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 118.16 33.27 5.83 -4.43 12.94

Syros Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.65 12.94 13.80 28.94 154.51

Competitive Comparison of Syros Pharmaceuticals's EV-to-Revenue

For the Biotechnology subindustry, Syros Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syros Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syros Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Syros Pharmaceuticals's EV-to-Revenue falls into.



Syros Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Syros Pharmaceuticals's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3.987/0.354
=11.26

Syros Pharmaceuticals's current Enterprise Value is €3.99 Mil.
Syros Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syros Pharmaceuticals  (FRA:0S90) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Syros Pharmaceuticals's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=0.0575/0.012
=4.79

Syros Pharmaceuticals's share price for today is €0.0575.
Syros Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Syros Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Syros Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Syros Pharmaceuticals Business Description

Traded in Other Exchanges
Address
35 CambridgePark Drive, 4th Floor, Cambridge, MA, USA, 02140
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.

Syros Pharmaceuticals Headlines

No Headlines